Gene Editing Weekly - Jun 26-Jul 3

Coverage spans June 26 at 09:35 through July 3 at 09:00 ET. The main change was Casgevy moving from an adolescent-and-adult product into early pediatric use: FDA expanded Vertex Pharmaceuticals and CRISPR Therapeutics' CRISPR/Cas9 cell therapy to patients age 2 and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), adding about 5,500 newly eligible U.S. children and clearing the supplement in 53 days under the Commissioner's National Priority Voucher pilot. 12

For investors and translational teams, the week had two linked reads. First, FDA is still willing to use compressed review pathways for high-need gene and cell therapy settings when the evidence package is already familiar. Second, that flexibility is running through an unstable CBER operating environment, with Vijay Kumar leaving as acting head of the Office of Therapeutic Products and Karim Mikhail taking that role in addition to acting CBER director. 3

Casgevy, or exagamglogene autotemcel, is an autologous ex vivo CRISPR/Cas9 therapy that edits a patient's own hematopoietic stem cells before reinfusion. FDA had previously approved it for patients age 12 and older; the July 1 expansion covers people age 2 and older with SCD and recurrent vaso-occlusive crises or with TDT. 12

The data package was small but directionally consistent with the original label. In CLIMB-141, 8 of 8 evaluable SCD patients ages 5 to 11 achieved VF12, defined as at least 12 consecutive months without severe vaso-occlusive crises during the first 24 months after infusion. 2 In CLIMB-151, 8 of 9 evaluable TDT patients ages 5 to 11 achieved transfusion independence for at least 12 months, with a median duration of 20.1 months. 2 The extension down to age 2 relied on extrapolation from clinical data and product characteristics, while CLIMB-141 and CLIMB-151 continue to evaluate children ages 2 to 11. 2

The commercial infrastructure is no longer hypothetical. Vertex said more than 75 authorized treatment centers are active in the United States, and the expanded label adds about 5,500 eligible children. 1 The near-term constraint is therefore less about whether the product is approved and more about pediatric referral, transplant-center capacity, conditioning tolerance, payer handling of earlier treatment, and family willingness to act before organ damage accumulates.

The 53-day CNPV review also matters. The CNPV pilot is still young, but Casgevy's expansion was the program's eighth approval, and it compressed what would normally be a much longer supplemental-review cycle. 2 For platform companies, the lesson is narrow: FDA can move fast when a therapy has an established product profile, a high-need pediatric extension, and an evidence bridge the agency accepts.

CBER's week had a split character. On the product side, FDA cleared or scheduled several complex biologics decisions. On the operating side, Kumar's departure added another senior-role transition at the Office of Therapeutic Products, which reviews gene therapies and cell therapies. 3 Healthcare Dive reported that Mikhail will serve as acting OTP director while FDA searches internally and externally for a permanent director. 3

Capricor's deramiocel advisory committee is the cleanest upcoming process anchor. FDA published a Federal Register notice on Jun 29 for a Cellular, Tissue, and Gene Therapies Advisory Committee meeting on Jul 29 from 10:00 a.m. to 4:30 p.m. ET to discuss BLA 125842 for deramiocel in Duchenne muscular dystrophy-related cardiomyopathy. 8 The public-comment deadline is Jul 20, and the docket is FDA-2026-N-6771. 8 Deramiocel is a cell therapy rather than gene editing, but the meeting will be watched by the same sponsors that depend on CBER's tolerance for small datasets, serious diseases, and surrogate or functional endpoints.

The broader evidence-policy signal remains in play. Arnold & Porter analyzed FDA's Jun 22 revised draft guidance on substantial evidence and described the operational shift as elevating one adequate and well-controlled clinical investigation plus confirmatory evidence from an exception toward a more routine development path. 9 The advisory also noted that confirmatory evidence may include mechanistic and biological information, natural-history or registry data, early clinical data, and evidence from related adequate and well-controlled studies. 9 For gene-editing sponsors, the useful part is not a lower bar. It is an earlier route to align the trial, biomarker, external-control, and platform-prior-knowledge arguments before the registrational package is locked.

TREGZI adds one more data point on CBER's willingness to approve operationally complex products. Orca Bio's therapy was approved for hematopoietic and immune reconstitution and improved chronic graft-versus-host-disease-free survival after matched-donor HSCT in adults with hematologic malignancies. 4 In the Precision-T Phase 3 study, one-year chronic GVHD-free survival was 78% for TREGZI versus 38% for conventional allogeneic HSCT, with HR 0.26 and p<0.00001; one-year overall survival was 94% versus 83%, with p=0.11823. 4 The wholesale acquisition cost is $428,000. 10

REGENXBIO's NAAVIGATE start is a real execution step because it ties clinical progress to partner economics. The company announced that the first patient with diabetic retinopathy was dosed in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec, also known as ABBV-RGX-314, delivered by suprachoroidal administration. 6 The dosing triggered a $100 million milestone payment from AbbVie to REGENXBIO. 6

NAAVIGATE is a multicenter, randomized, double-masked, sham-controlled trial in patients with moderately severe to severe nonproliferative diabetic retinopathy without center-involved diabetic macular edema. 6 The Phase IIb portion is expected to enroll about 135 U.S. patients, and the primary endpoint is a greater-than-two-step improvement on the Diabetic Retinopathy Severity Scale at one year. 6 REGENXBIO plans to present 2.5-year ALTITUDE diabetic-retinopathy follow-up and five-year wet AMD Phase I/IIa data at ASRS 2026 in July, while ATMOSPHERE and ASCENT registrational wet AMD topline data are expected in Q4 2026. 6

Beam's BEAM-304 clearance gives the in vivo base-editing field another clinical entry point. BEAM-304 targets PKU by using LNP delivery and mutation-specific base editors intended to correct PAH gene variants and restore PAH enzyme activity. 5 Drug Discovery World reported that PKU affects about 20,000 people in the United States and that preclinical mouse data showed normalized plasma phenylalanine at clinically relevant doses. 5 The investment question is whether one clinical program can efficiently carry several mutation-specific editors without creating separate CMC and comparability problems for each variant.

Voyager Therapeutics added a near-term conference marker for VY1706, its tau-targeted AAV gene therapy for Alzheimer disease. The company said VY1706 will be presented in a Developing Topics poster at AAIC 2026 in London, scheduled for Jul 12-15. 11 VY1706 uses vectorized siRNA against MAPT mRNA and a TRACER AAV capsid designed to cross the blood-brain barrier through the ALPL receptor after one-time intravenous dosing. 11 Voyager said prior GLP nonhuman-primate toxicology showed tolerability up to 5E13 vg/kg and tau-protein lowering of up to 75% in brain regions relevant to Alzheimer disease; the program has FDA IND clearance and is expected to begin first-in-human dosing in H2 2026. 11

Sangamo's fresh filing did not answer the central asset-sale question. The Jul 1 Form 8-K said the audit committee terminated Ernst & Young on Jun 25, that EY's audit reports for fiscal 2024 and fiscal 2025 contained going-concern explanatory paragraphs but no adverse opinion or disclaimer, and that Sangamo had not yet engaged a new independent registered public accounting firm. 7 The same filing said SGMOQ began trading on the OTCID Basic Market on Jun 24 and that the Nasdaq appeal remained pending. 7 No new competing bid, auction date, or Chapter 11 sale milestone was disclosed in that filing. 7

Abu Dhabi's three BIO 2026 agreements point to another kind of execution capacity: jurisdictional infrastructure. The Department of Health - Abu Dhabi signed agreements with Children's Hospital of Philadelphia, Mammoth Biosciences through M42, and Arbor Biotechnologies to support rare-disease gene-editing translation, clinical research, advanced-therapy manufacturing, and R&D tied to the Emirati Genome Program. 12 This is not a single-product catalyst, but it is a reminder that population-scale genomics, manufacturing capacity, and permissive clinical infrastructure are becoming part of the competition for where editing programs are developed.

Nature's Jun 26 feature on epigenome editing described a modality that is moving from academic pitch to early clinical testing. Epicrispr Biotechnologies, nChroma, and Tune Therapeutics were identified as companies pursuing therapeutic epigenome editing, which changes gene-control marks rather than the DNA sequence itself. 13 Nature reported that nChroma began dosing an experimental epigenetic silencer for chronic hepatitis B in Jan 2026 and that a 2025 monkey study showed a single injection reduced PCSK9 and LDL cholesterol by about 70%. 13 The platform appeal is clear, but the risk category is different from nuclease editing: durability, reversibility, tissue specificity, and developmental epigenetic effects will matter as much as classic off-target DNA editing.

The standards discussion moved in parallel. A Jul 1 Nature Perspective called for harmonized medical-genome standards across germline sequencing, tumor sequencing, cell-free DNA testing, and gene-therapy quality-control sequencing. 14 The abstract specifically points to the challenge of accurately detecting low-frequency genetic variants in gene-edited cells. 14 That is a practical manufacturing and release-testing issue, not only a diagnostics issue, because edited-cell products increasingly depend on proving rare unwanted variants are absent or controlled.

Publication volume stayed high. Europe PMC's search for gene-editing-related publications from Jun 26 through Jul 3 returned 507 items, including 11 preprints, 350 research articles, and 146 reviews. 15 The higher-signal translational items in the package included inducible CRISPR/Cas systems in precision oncology, CRISPR/Cas9 evidence for a nonredundant role of p16INK4A in CD8 T-cell expansion, and reviews on precision gene editing and familial hemophagocytic lymphohistiocytosis. 16171819

The embryo-editing governance gap remained unresolved in the checked sources. WHO's human genome editing page still pointed to the July 2021 governance framework, and Nuffield Council's genome-editing page still listed its 2016 ethical review and 2018 human-reproduction report. 2021 The bounded conclusion is that the visible institutional response in this research package has not caught up with the June embryo-editing papers.